Protocol I8K-MC-JPDA-A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of LY3337641 in Adult Subjects With Moderate to Severe Rheumatoid Arthritis: The RAjuvenate Study

Trial Profile

Protocol I8K-MC-JPDA-A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of LY3337641 in Adult Subjects With Moderate to Severe Rheumatoid Arthritis: The RAjuvenate Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Poseltinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAjuvenate
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jan 2017 Planned number of patients changed from 182 to 276.
    • 06 Jan 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top